A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

This study is testing a drug called SHR-A1811 (an antibody-drug conjugate that delivers chemotherapy directly to cancer cells) in combination with standard chemotherapy for patients with advanced breast cancer. The study focuses on patients whose cancer expresses high levels of HER2 or has not responded to prior treatments. **You may be eligible if...** - You have advanced breast cancer with measurable tumors on scans - Your cancer has specific characteristics (e.g., HER2-positive or other subtypes being enrolled) - Your general health score (ECOG) is 0 or 1 - Your expected survival is at least 12 weeks - You are willing and able to use contraception **You may NOT be eligible if...** - You have untreated brain metastases or cancer spread to the lining of the brain - You have significant fluid around your lungs, heart, or abdomen that is uncontrolled - You have serious heart, liver, or lung conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.